Group 1: Company Overview - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. focuses on high-performance implantable medical devices, specifically in the neurosurgery field, offering products such as artificial dura mater patches and absorbable regenerative fibers [4][5]. - The company aims to provide comprehensive solutions for key implantable medical devices required in craniotomy surgeries [4]. Group 2: Recent Investor Relations Activity - The investor relations activity included a teleconference held on June 6, 2025, with participation from various securities firms and investment entities [2][4]. - Key personnel involved in the meeting included the Chairman and Vice General Managers, highlighting the company's commitment to transparency and communication with investors [4]. Group 3: Strategic Acquisition - The company plans to acquire 100% equity of Yijie Medical through a combination of issuing shares and cash payments, involving 10 transaction parties [10]. - This acquisition is expected to enhance the company's capabilities in the interventional medical device sector, leveraging Yijie Medical's expertise in biocompatible materials [5][10]. Group 4: Market Position and Future Plans - Yijie Medical has established a marketing team with extensive experience in promoting neuro-interventional medical devices, successfully entering major hospitals [6][7]. - The company is focused on maintaining a balance between organic growth and strategic acquisitions to enhance shareholder value and market presence [10]. Group 5: Regulatory and Financial Considerations - The asset evaluation and auditing for the acquisition are ongoing, with the final transaction price to be determined based on regulatory assessments [8]. - The company will adhere to regulatory requirements, including shareholder approval and necessary disclosures to the Shenzhen Stock Exchange and the China Securities Regulatory Commission [8].
迈普医学(301033) - 2025年6月6日投资者关系活动记录表